Annual report pursuant to Section 13 and 15(d)

Note 1 - Corporate Information (Details Textual)

v3.24.1
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Mar. 27, 2024
Jul. 18, 2023
May 31, 2013
Reduction in Workforce, Percentage       70.00%  
Reduction in Workforce, Cost $ 7,500        
Cash, Cash Equivalents, and Short-Term Investments 26,400        
Net Income (Loss) Attributable to Parent (24,543) $ (33,277)      
Retained Earnings (Accumulated Deficit) $ (314,964) $ (290,421)      
Subsequent Event [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]          
Contracts Receivable, Claims and Uncertain Amounts     $ 20,000    
Subsequent Event [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]          
Contracts Receivable, Claims and Uncertain Amounts     $ 55,000    
Pieris Pharmaceuticals GmbH [Member]          
Business Acquisition, Percentage of Voting Interests Acquired         100.00%